ClinicalTrials.gg
CompletedNCT07543198Updated Apr 21, 2026

Clinical Trial of PCV24 in Adults Aged ≥18 Years

A Phase 1/2 interventional study of Sinovac Low-dosage PCV24 and Sinovac Middle-dosage PCV24 in Pneumococcal Infectious Disease, sponsored by Sinovac Life Sciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Sinovac Life Sciences Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2025, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
385
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Sinovac Biotech Co., Ltd.

Enrollment
7th of 12
385 · median 403
Started
2025
with 2 others
Phase 1/2
Only one
of the 13
Registered
13th of 13
by date

Among the 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 1/2, and was the 13th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

3 of the 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

A Phase Ib/II clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24)developed by Sinovac Life Science Co., Ltd will be conducted in adults aged ≥18 years.

The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, Positive Controlled phase Ib/II clinical trial.

Read the detailed description

A phase Ib/II clinical trial of the study of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Chinese adults aged ≥18years.

The trial is a randomized, double-blind, positive controlled study. The objective of this study is to evaluate the safety and immunogenicity of PCV24 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine is Pneumovax® manufactured by MSD.

03

Conditions studied

  • Pneumococcal Infectious Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults aged ≥18 years, who can provide legal identification documents
  2. Fully understand and agree to sign the form
  3. Willing and able to follow all study procedures and stay in contact during the study

Exclusion criteria

Exclusion Criteria:

  1. Received any pneumococcal vaccine;
  2. History of invasive pneumococcal diseases or other pneumococcal diseases caused by Streptococcus pneumoniae, as confirmed by laboratory tests;
  3. History of allergy or serious adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioedema and anaphylactic shock;
  4. Congenital malformations or developmental disorders, genetic defects, severe malnutrition;
  5. Have uncontrolled chronic diseases or history of severe diseases, including but not limited to cardiovascular diseases, metabolic diseases, hematological diseases,liver and kidney diseases, digestive diseases, respiratory diseases , malignant tumors and major functional organ transplantation history;
  6. diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis,autoimmune thyroid disease, asplenia, functional asplenia, infection);
  7. Abnormalities in coagulation function (such as deficiency of coagulation factors, coagulation disorders, and abnormalities of );
  8. Have/have suffered from a serious neurological disorder (epilepsy , convulsions or seizures) or mental illness or have a family history of such diseases;
  9. Long-term alcohol or drug abuse;
  10. Have received > 14 days of or other immunomodulatory therapy((such as prednisone ≥20 mg/day, or an equivalent dose)) in the past 6 months, or cytotoxic therapy, or plan to receive such therapy during the study period;
  11. Received immunoglobulin or other blood products within 3 months before receiving the l vaccine, or plan to receive such treatment during the study period;
  12. Received other drugs or vaccines within 30 days before receiving the vaccine, or plan to receive such drugs or vaccines during the study;
  13. Received within 14 days before receiving the vaccine;
  14. Received subunit or inactivated or other vaccine within 7 days before receiving the vaccine;
  15. Acute diseases or acute onset of chronic diseases within the past 7 days , or known or suspected active infection;
  16. Women who are breastfeeding or pregnant, or women of who plan to become pregnant or have egg donation plans from the time of signing the form until 6 months after the study intervention;
  17. Participants who have a fever on the day of the planned trial vaccine, with an axillary temperature >37.0°C before vaccination;
  18. Abnormalities in clinical laboratory indicators that exceed reference range and are (Applicable only to phase Ib)
  19. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
385 participants (actual)

Study arms

  • Experimental
    Low-dosage PCV24 (phase Ib)

    12 Participants aged 18-49years and 12 Participants aged ≥50years will receive Sinovac Low-dosage PCV24 . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Sinovac Low-dosage PCV24

  • Experimental
    Middle-dosage PCV24(phase Ib)

    12 Participants aged 18-49 years and 12 Participants aged ≥50years will receive Sinovac Middle-dosage PCV24 . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Sinovac Middle-dosage PCV24

  • Experimental
    High-dosage PCV24(phase Ib)

    12 Participants aged 18-49years will receive Sinovac High-dosage PCV24 . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Sinovac High-dosage PCV24

  • Active comparator
    Pneumovax®(phase Ib)

    12 Participants aged 18-49years and 6 Participants aged ≥50years will receive Pneumovax®(PPV23) . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Pneumovax®

  • Experimental
    Low-dosage PCV24(phase II)

    50 Participants aged 18-49years and 50 Participants aged ≥50years will receive Sinovac Low-dosage PCV24 . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Sinovac Low-dosage PCV24

  • Experimental
    Middle-dosage PCV24(phase II)

    50 Participants aged 18-49years and 50 Participants aged ≥50years will receive Sinovac Middle-dosage PCV24 . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Sinovac Middle-dosage PCV24

  • Active comparator
    Pneumovax®(phase II)

    50 Participants aged 18-49years and 50 Participants aged ≥50years will receive Pneumovax®(PPV23) . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Pneumovax®

Interventions

  • BiologicalSinovac Low-dosage PCV24

    One dose of Sinovac Low-dosage PCV24 (0.5mL)

  • BiologicalSinovac Middle-dosage PCV24

    One dose of Sinovac Middle-dosage PCV24(0.5mL)

  • BiologicalSinovac High-dosage PCV24

    One dose of Sinovac High-dosage PCV24(0.5mL)

  • BiologicalPneumovax®

    One dose of PPV23 manufactured by MSD

06

What researchers measure

Primary outcomes

  1. Incidence of adverse reactions

    Incidence of adverse reactions of different doses of PCV24 in adults aged ≥18 years within 30 days after vaccination

    Time frame: 0-30 days after vaccination

  2. Pneumococcal serotype-specific opsonophagocytic assay (OPA) geometric mean titer (GMT) (phase II)

    OPA GMT 30 days after vaccination

    Time frame: 30 days after vaccination

  3. Proportion of pneumococcal serotype-specific OPA antibody titer increase≥4-fold(phase II)

    Proportion of OPA antibody titer increase≥four folds 30 days after vaccination

    Time frame: 30 days after vaccination

  4. Pneumococcal serotype-specific IgG antibody geometric mean concentration (GMC)(phase II)

    IgG GMC 30 days after vaccination

    Time frame: 30 days after vaccination

  5. Proportion of pneumococcal serotype-specific IgG antibody concentration increase≥4-fold(phase II)

    Proportion of IgG antibody concentration increase≥four folds 30 days after vaccination

    Time frame: 30 days after vaccination

Secondary outcomes

  1. Incidence of clinically significant abnormality in laboratory examination tests(phase Ib)

    Incidence of clinically significant abnormality in blood routine, blood biochemistry and urine routine test results within 3 days after vaccination

    Time frame: 0-3 days after vaccination

  2. Incidence of adverse reactions

    Incidence of adverse reactions within 7 days after vaccination

    Time frame: 0-7 days after vaccination

  3. Incidence of serious adverse reactions(SAE)

    Incidence of SAE within 6 months after vaccination

    Time frame: 0-6 months after vaccination

  4. Pneumococcal serotype-specific OPA GMI(phase II)

    OPA GMI 30 days after vaccination

    Time frame: 30 days after vaccination

  5. Pneumococcal serotype-specific IgG antibody geometric mean increase (GMI)(phase II)

    IgG GMI 30 days after vaccination

    Time frame: 30 days after vaccination

07

Study locations

1 site
  • Shaanxi Provincial Center for Disease Control and Prevention
    Xi'an, Shaanxi, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Feb 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 21, 2026
StartActual
Jun 18, 2025
Primary completionActual
Feb 26, 2026
CompletionActual
Feb 26, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07543198
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Jun 18, 2025
Primary completion
Feb 26, 2026
Completion
Feb 26, 2026
Last update
Apr 21, 2026

Study contacts

Weijun Hu
principal investigator · Shaanxi Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion